Ibrahim Yalcin1, Mehmet Mutlu Meydanli2, Ahmet Taner Turan3, Salih Taskin4, Mustafa Erkan Sari2, Tayfun Gungor2, Ozgur Akbayir5, Ali Ayhan6. 1. Department of Gynecologic Oncology, Faculty of Medicine, Zekai Tahir Burak Women's Health Research and Training Hospital, University of Health Sciences, Zekai Tahir Burak Kadın Saglıgı Egitim ve Arastırma Hastanesi, Talatpasa Bulvarı, Altındag, 06230, Ankara, Turkey. ibrahimyalcin73@gmail.com. 2. Department of Gynecologic Oncology, Faculty of Medicine, Zekai Tahir Burak Women's Health Research and Training Hospital, University of Health Sciences, Zekai Tahir Burak Kadın Saglıgı Egitim ve Arastırma Hastanesi, Talatpasa Bulvarı, Altındag, 06230, Ankara, Turkey. 3. Department of Gynecologic Oncology, Faculty of Medicine, Etlik Zubeyde Hanim Women's Health Research and Training Hospital, University of Health Sciences, Etlik Mahallesi, Yeni Etlik Caddesi No: 55, 06010, Ankara, Turkey. 4. Department of Gynecologic Oncology, Faculty of Medicine, Ankara University, Mamak Cad., Cebeci, Ankara, Turkey. 5. Department of Gynecologic Oncology, Kanuni Sultan Suleyman Research and Training Hospital, Atakent Mah. 1. Sk. No: 46, Küçükçekmece, Istanbul, Turkey. 6. Department of Gynecologic Oncology, Faculty of Medicine, Baskent University, Y. Bahcelievler Mah., Mareşal Fevzi Çakmak Cad., No: 45, Çankaya, Ankara, Turkey.
Abstract
OBJECTIVE: The purpose of this retrospective study was to compare the prognoses of women with ovarian carcinosarcoma (OCS) who had optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy to those of women with ovarian high-grade serous carcinoma (HGSC) treated in the same manner. METHODS: A multicenter, retrospective department database review was performed to identify patients with OCS at eight gynecologic oncology centers in Turkey. A total of 54 women with OCS who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy between 1999 and 2017 were included in this case-control study. Each case was matched to two women with ovarian HGSC who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy. The Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analysed using Cox proportional hazards models. RESULTS: Median disease-free survival (DFS) was 29 months [95% confidence interval (CI) 0-59, standard error (SE) 15.35] versus 27 months (95% CI 22.6-31.3, SE 2.22; p = 0.765) and median overall survival (OS) was 62 versus 82 months (p = 0.53) for cases and controls, respectively. For the entire cohort, the presence of ascites [hazard ratio (HR) 2.32; 95% CI 1.02-5.25, p = 0.04] and platinum resistance [HR 5.05; 95% CI 2.32-11, p < 0.001] were found to be independent risk factors for decreased OS. CONCLUSION: DFS and OS rates of patients with OCS and HGSC seem to be similar whenever optimal cytoreduction is achieved and followed by platinum plus taxane combination chemotherapy.
OBJECTIVE: The purpose of this retrospective study was to compare the prognoses of women with ovarian carcinosarcoma (OCS) who had optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy to those of women with ovarian high-grade serous carcinoma (HGSC) treated in the same manner. METHODS: A multicenter, retrospective department database review was performed to identify patients with OCS at eight gynecologic oncology centers in Turkey. A total of 54 women with OCS who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy between 1999 and 2017 were included in this case-control study. Each case was matched to two women with ovarian HGSC who had undergone optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy. The Kaplan-Meier method was used to generate survival data. Factors predictive of outcome were analysed using Cox proportional hazards models. RESULTS: Median disease-free survival (DFS) was 29 months [95% confidence interval (CI) 0-59, standard error (SE) 15.35] versus 27 months (95% CI 22.6-31.3, SE 2.22; p = 0.765) and median overall survival (OS) was 62 versus 82 months (p = 0.53) for cases and controls, respectively. For the entire cohort, the presence of ascites [hazard ratio (HR) 2.32; 95% CI 1.02-5.25, p = 0.04] and platinum resistance [HR 5.05; 95% CI 2.32-11, p < 0.001] were found to be independent risk factors for decreased OS. CONCLUSION: DFS and OS rates of patients with OCS and HGSC seem to be similar whenever optimal cytoreduction is achieved and followed by platinum plus taxane combination chemotherapy.
Authors: Erin M George; Thomas J Herzog; Alfred I Neugut; Yu-Shiang Lu; William M Burke; Sharyn N Lewin; Dawn L Hershman; Jason D Wright Journal: Gynecol Oncol Date: 2013-07-06 Impact factor: 5.482
Authors: Uma Krishnamurti; Eizaburo Sasatomi; Patricia A Swalsky; Mirka W Jones; Sydney D Finkelstein Journal: Int J Gynecol Pathol Date: 2005-01 Impact factor: 2.762
Authors: Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: William E Winter; G Larry Maxwell; Chunqiao Tian; Michael J Sundborg; G Scott Rose; Peter G Rose; Stephen C Rubin; Franco Muggia; William P McGuire Journal: J Clin Oncol Date: 2007-11-19 Impact factor: 44.544
Authors: Linda R Duska; Audrey Garrett; Gamal H Eltabbakh; Esther Oliva; Richard Penson; Arlan F Fuller Journal: Gynecol Oncol Date: 2002-06 Impact factor: 5.482
Authors: Robert L Hollis; Ian Croy; Michael Churchman; Clare Bartos; Tzyvia Rye; Charlie Gourley; C Simon Herrington Journal: Br J Cancer Date: 2022-06-17 Impact factor: 9.075